Evogenix evogenix.com.au


Public lists: Pharma Startups (4733)

Evogenix aims to provide advanced technologies to provide powerful new antibody therapeutics for world markets.

Evogenix aims to provide advanced technologies to provide powerful new antibody therapeutics for world markets.

Company (Alive / Active)

Phone: (+6) 128-061-9900

Fax: +612 8061 9999

37 Epping Road
Level 2
2113
Australia

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Evogenix $0M Oct 4, 2018
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Evogenix Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Kereos

St. Louis, Missouri, United States
Alive / ActiveKereos develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than currently possible. The specificity and capabilities of Kereos' molecular imaging agents enable earlier and more definitive diagnosis of disease. Similarly, Kereos' targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, making them potentially more effective and less toxi...Show allLogin to see details

Nuon Therapeutics

San Mateo, California, United States
Alive / ActiveNuon Therapeutics discovers novel uses for marketed drugs. The advantage of this approach is that the development program for the marketed indication will have investigated the compounds toxicity and established its tolerability. This makes it possible to proceed directly to clinical trials once the efficacy of the compound has been established in animal models. The costs and risks involved in the drug development process are greatly reduced. Tranilast is under development for the treatment of p...Show allLogin to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Osteoprotegerin variant proteins Dec 13, 2005 Nov 03, 2009 Patent